Neuphoria Agrees to All-Share Merger with Scancell, $89M Financing Secured
NEUP sits 25% above its 52-week low of $3.19.
Summary
Neuphoria Therapeutics has entered a definitive all-share merger agreement with Scancell, moving beyond the discussion phase reported in late June. Under the terms, Scancell shareholders will own 85.5% of the combined entity, leaving Neuphoria shareholders with 14.5%. Scancell also expects to secure up to $89 million in financing, which will bolster the combined company's cash position. This follows Neuphoria's recent Phase 3 trial setback and its efforts to extend its cash runway through equity sales and milestone payments. The merger provides a strategic path forward, potentially de-risking Neuphoria's pipeline and offering immediate scale. The financing component addresses near-term liquidity concerns, making this a transformative event for the micro-cap biotech.
At the time of this announcement, NEUP was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18M. The 52-week trading range was $3.19 to $21.40. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.